Your browser is no longer supported. Please, upgrade your browser.
Settings
ALIM Alimera Sciences, Inc. daily Stock Chart
ALIM [NASD]
Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own1.80% Shs Outstand4.98M Perf Week-1.97%
Market Cap26.50M Forward P/E- EPS next Y-0.50 Insider Trans1.07% Shs Float4.13M Perf Month-1.20%
Income-8.90M PEG- EPS next Q-1.51 Inst Own44.50% Short Float0.10% Perf Quarter-30.25%
Sales55.60M P/S0.48 EPS this Y-159.00% Inst Trans-12.63% Short Ratio0.20 Perf Half Y0.98%
Book/sh-7.18 P/B- EPS next Y71.80% ROA-18.10% Target Price- Perf Year-62.75%
Cash/sh2.31 P/C2.17 EPS next 5Y- ROE25.10% 52W Range- - 15.45 Perf YTD-33.65%
Dividend- P/FCF- EPS past 5Y-19.30% ROI-124.80% 52W High-67.45% Beta2.24
Dividend %- Quick Ratio3.40 Sales past 5Y45.00% Gross Margin87.50% 52W Low- ATR0.41
Employees122 Current Ratio3.50 Sales Q/Q12.40% Oper. Margin-6.60% RSI (14)46.83 Volatility4.87% 8.59%
OptionableNo Debt/Eq- EPS Q/Q58.90% Profit Margin-16.00% Rel Volume0.54 Prev Close5.26
ShortableYes LT Debt/Eq- EarningsApr 29 AMC Payout- Avg Volume20.15K Price5.03
Recom2.20 SMA20-7.88% SMA505.25% SMA200-15.71% Volume10,875 Change-4.39%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
May-11-20 01:00PM  Edited Transcript of ALIM earnings conference call or presentation 30-Apr-20 1:00pm GMT Thomson Reuters StreetEvents
Apr-30-20 08:30PM  Alimera Sciences Inc (ALIM) Q1 2020 Earnings Call Transcript Motley Fool +6.09%
Apr-29-20 06:25PM  Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:00PM  Alimera Sciences Announces First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Apr-24-20 08:00AM  Alimera Sciences to Report First Quarter 2020 Financial Results on Wednesday, April 29, 2020 and Provide Corporate Update GlobeNewswire
Apr-23-20 08:00AM  Alimera Sciences Receives $1.8 Million Loan Under the Paycheck Protection Act GlobeNewswire
Apr-13-20 08:36AM  Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update GlobeNewswire +18.12%
Mar-31-20 12:43PM  Penny Stocks to Buy Using Technical Analysis for April 2020 Investopedia +10.80%
08:00AM  Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement GlobeNewswire
Mar-26-20 08:18AM  Edited Transcript of ALIM earnings conference call or presentation 27-Feb-20 2:00pm GMT Thomson Reuters StreetEvents
Mar-25-20 08:00AM  Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference GlobeNewswire +25.96%
Feb-29-20 07:32AM  Analysts Have Been Trimming Their Alimera Sciences, Inc. Price Target After Its Latest Report Simply Wall St.
Feb-26-20 06:35PM  Alimera Sciences (ALIM) Tops Q4 Earnings and Revenue Estimates Zacks -6.09%
04:05PM  Alimera Sciences Reports Record Fourth Quarter and 2019 Results GlobeNewswire
Feb-24-20 08:00AM  Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement GlobeNewswire
Feb-20-20 08:00AM  Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update GlobeNewswire +6.83%
Jan-29-20 04:52AM  Insider Buying: The Alimera Sciences, Inc. (NASDAQ:ALIM) Just Bought US$562k Worth Of Shares Simply Wall St.
Jan-27-20 08:11AM  Alimera Sciences, Inc 13D/A filing PR Newswire -9.15%
Jan-10-20 04:11PM  2 Healthcare Stocks Set to Rally into the New Year TipRanks
Jan-06-20 08:00AM  Alimera Sciences Refinances Its Debt Facility With Solar Capital GlobeNewswire
Dec-17-19 07:20PM  Did Hedge Funds Drop The Ball On Alimera Sciences Inc (ALIM) ? Insider Monkey
Dec-11-19 12:01PM  Almira Sciences, Inc 13D filing PR Newswire
Dec-04-19 08:30AM  Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019 GlobeNewswire +6.22%
Dec-03-19 08:30AM  Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis GlobeNewswire
Nov-26-19 08:30AM  Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-20-19 03:32AM  Edited Transcript of ALIM earnings conference call or presentation 30-Oct-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 12:45PM  Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split GlobeNewswire +17.31%
Nov-13-19 08:00AM  Alimera Sciences Terminates Equity Purchase Agreement GlobeNewswire +13.04%
Nov-08-19 08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga -12.57%
Nov-07-19 06:00PM  Alimera Sciences Announces Boards Approval of Reverse Stock Split Ratio GlobeNewswire -5.34%
Nov-05-19 08:30AM  Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York GlobeNewswire +5.45%
05:06AM  One Thing To Remember About The Alimera Sciences, Inc. (NASDAQ:ALIM) Share Price Simply Wall St.
Oct-29-19 04:42PM  Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
07:32AM  The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga
Oct-25-19 08:30AM  Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital GlobeNewswire
Oct-23-19 08:30AM  Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update GlobeNewswire
Oct-03-19 08:30AM  Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis GlobeNewswire
Oct-02-19 08:00AM  Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019 GlobeNewswire -10.20%
Oct-01-19 08:00AM  Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting GlobeNewswire -13.47%
Sep-12-19 08:00AM  Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries GlobeNewswire +12.89%
Sep-05-19 08:00AM  Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management GlobeNewswire
Sep-03-19 08:00AM  Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication GlobeNewswire -8.61%
Aug-06-19 07:24AM  How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own? Simply Wall St.
Aug-05-19 08:00AM  Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema GlobeNewswire
Aug-03-19 09:25AM  Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT Thomson Reuters StreetEvents
Jul-29-19 06:51PM  Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-23-19 08:00AM  Alimera Sciences Announces Multiple Papers On Demand at the 2019 American Society of Retina Specialists Annual Meeting GlobeNewswire
Jul-22-19 08:00AM  Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update GlobeNewswire
Jul-19-19 08:00AM  Alimera Sciences Announces the Appointment of Industry Veteran and Ophthalmology Business Executive John Snisarenko to its Board of Directors GlobeNewswire
Jun-20-19 09:12AM  Did Changing Sentiment Drive Alimera Sciences's (NASDAQ:ALIM) Share Price Down A Painful 85%? Simply Wall St.
08:00AM  Alimeras ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis GlobeNewswire
Jun-06-19 08:00AM  Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment GlobeNewswire
Jun-04-19 05:34AM  Alimera Sciences Sees Hammer Chart Pattern: Time to Buy? Zacks
May-22-19 08:00AM  Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN® GlobeNewswire -8.88%
May-21-19 08:24AM  Top Ranked Momentum Stocks to Buy for May 21st Zacks
May-14-19 08:05AM  Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 GlobeNewswire
May-05-19 11:04PM  Edited Transcript of ALIM earnings conference call or presentation 30-Apr-19 1:00pm GMT Thomson Reuters StreetEvents
Apr-29-19 04:15PM  Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview GlobeNewswire
Apr-23-19 04:30PM  Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update ACCESSWIRE
08:30AM  Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting ACCESSWIRE
Apr-04-19 08:00AM  Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer ACCESSWIRE
Mar-25-19 09:28AM  Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe ACCESSWIRE
Mar-21-19 08:00AM  Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait ACCESSWIRE -6.19%
Mar-06-19 08:00AM  Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France ACCESSWIRE
Feb-20-19 03:43PM  Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
10:31AM  Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know Zacks
Feb-19-19 07:00AM  Alimera Sciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-19 04:15PM  Alimera Sciences Reports Record Fourth Quarter and 2018 Results ACCESSWIRE
Feb-05-19 07:30AM  Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon ACCESSWIRE
Feb-04-19 07:30AM  Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019 ACCESSWIRE
Jan-30-19 11:07AM  Eye implant is helping treat vision loss in diabetics Yahoo Finance Video
Jan-07-19 06:30AM  Alimera Sciences Affirms Record 2018 Revenues ACCESSWIRE
Dec-21-18 11:36AM  What Type Of Shareholder Owns Alimera Sciences, Inc.s (NASDAQ:ALIM)? Simply Wall St.
Dec-17-18 07:00AM  Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E. ACCESSWIRE
Nov-29-18 07:15AM  Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer ACCESSWIRE
Nov-26-18 03:30PM  Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R) ACCESSWIRE
Nov-21-18 08:25AM  Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-18-18 09:30PM  Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 06:30AM  Alimera Sciences to Present at Upcoming Investor Conferences ACCESSWIRE
Nov-06-18 07:30AM  Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:03AM  Alimera Sciences: 3Q Earnings Snapshot Associated Press
Nov-05-18 06:45PM  Alimera Sciences Reports Third Quarter 2018 Results ACCESSWIRE
Oct-23-18 04:45PM  Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018 ACCESSWIRE
Oct-22-18 04:30PM  Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology ACCESSWIRE
Oct-15-18 03:57PM  How Alimera Sciences Inc (NASDAQ:ALIM) Can Impact Your Portfolio Volatility Simply Wall St.
Sep-17-18 05:32PM  Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress PR Newswire
Sep-13-18 04:30PM  Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting PR Newswire
Sep-04-18 05:43PM  Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock PR Newswire
Aug-29-18 07:30AM  Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference PR Newswire
Aug-28-18 07:30AM  Alimera Sciences to Present at the Annual B. Riley Healthcare Conference PR Newswire
Aug-23-18 06:42AM  Alimera Sciences Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-06-18 09:19PM  Edited Transcript of ALIM earnings conference call or presentation 31-Jul-18 1:00pm GMT Thomson Reuters StreetEvents -11.99%
Jul-31-18 07:00AM  Alimera Sciences, Inc. to Host Earnings Call ACCESSWIRE
Jul-30-18 05:41PM  Alimera Sciences: 2Q Earnings Snapshot Associated Press
04:30PM  Alimera Sciences Reports Second Quarter 2018 Results PR Newswire
Jul-18-18 07:30AM  Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018 PR Newswire +10.10%
Jul-11-18 07:30AM  Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting PR Newswire
Jul-05-18 09:10AM  Alimera Stock Grew 25 Percent and It Is Just Getting Warmed Up InvestorPlace
Jun-29-18 02:50PM  B. Riley FBR: 3 Reasons To Buy Alimera Sciences Benzinga +6.35%
Jun-27-18 11:24AM  When Will Alimera Sciences Inc (NASDAQ:ALIM) Turn A Profit? Simply Wall St.
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones John PhilipChief Financial OfficerDec 10Buy9.291,0009,2949,536Dec 11 04:20 PM
Snisarenko JohnDirectorNov 21Buy4.9510,00049,50010,000Nov 25 04:17 PM
Largent James RDirectorNov 19Buy5.113,00015,3443,000Nov 20 05:19 PM